Skip Nav Destination
Issues
1 August 2023
-
Cover Image
Cover Image
ABBV-184 drives lymphocyte infiltration into established tumors in humanized CD34+NSG mice (Created in BioRender.com). Read the full article on page 903. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
First Disclosures
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies
Adam S. Chervin; Jennifer D. Stone; Iwona Konieczna; Kelly M. Calabrese; Ningyan Wang; Dipica Haribhai; Feng Dong; Michael K. White; Luis E. Rodriguez; Gail T. Bukofzer; Paul A. Ellis; Cormac Cosgrove; Claudie Hecquet; Jerry D. Clarin; Joann P. Palma; Edward B. Reilly
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Wei Zhou; Peng Fang; Dongan Yu; Hongyuan Ren; Meng You; Long Yin; Fei Mei; Huikai Zhu; Zhenzhen Wang; Hui Xu; Yuxia Cao; Xiaowei Sun; Xiaohong Xu; Jianjun Bi; Jin Wang; Lanping Ma; Xin Wang; Lin Chen; Yongliang Zhang; Xiaowei Cen; Xi Zhu; Liguang Lou; Datao Liu; Xiaoding Tan; Jinliang Yang; Tao Meng; Jingkang Shen
Review
Small Molecule Therapeutics
Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer
Susmita Ghosh; Fan Fan; Reid T. Powell; Jason Roszik; Yong Sung Park; Clifford Stephan; Manu Sebastian; Lin Tan; Alexey V. Sorokin; Philip L. Lorenzi; Scott Kopetz; Lee M. Ellis; Rajat Bhattacharya
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.